JAK
Les inhibiteurs de la kinase Janus (JAK) sont des composés qui ciblent la voie de signalisation JAK-STAT, impliquée dans la croissance cellulaire, la réponse immunitaire et l'angiogenèse. En inhibant JAK, ces composés peuvent réduire la signalisation qui conduit à la formation de nouveaux vaisseaux sanguins dans les tumeurs, inhibant ainsi la croissance tumorale. Les inhibiteurs de JAK sont importants dans le traitement des cancers et des maladies inflammatoires. Chez CymitQuimica, nous offrons une gamme diversifiée d'inhibiteurs de JAK de haute qualité pour soutenir vos recherches en oncologie, immunologie et angiogenèse.
245 produits trouvés pour "JAK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Tyrphostin AG 490
CAS :Formule :C17H14N2O3Degré de pureté :>98.0%(T)(HPLC)Couleur et forme :White to Light yellow powder to crystalMasse moléculaire :294.31Ilginatinib hydrochloride
CAS :<p>Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.</p>Formule :C21H21ClFN7Degré de pureté :99.55%Couleur et forme :SolidMasse moléculaire :425.89TAK-901
CAS :<p>TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others</p>Formule :C28H32N4O3SDegré de pureté :99.02% - 99.59%Couleur et forme :SolidMasse moléculaire :504.64N-(3-Aminopropyl)cyclohexylamine
CAS :<p>N-(3-Aminopropyl)cyclohexylamine inhibits spermine synthase; used in neuro disease research.</p>Formule :C9H20N2Degré de pureté :98.05% - 98.82%Couleur et forme :Pale Yellow Clear LiquidMasse moléculaire :156.2685Brepocitinib P-Tosylate
CAS :<p>Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).</p>Formule :C25H29F2N7O4SDegré de pureté :99.82% - 99.97%Couleur et forme :SolidMasse moléculaire :561.6WDR5-IN-6
CAS :<p>WDR5-IN-6 is a WDR5 inhibitor targeting the WBM locus.WDR5-IN-6 is highly synergistic with OICR-9429, a WDR5 inhibitor that targets the WIN locus.WDR5-IN-6</p>Formule :C13H8Cl2N2O2SDegré de pureté :99.69%Couleur et forme :SoildMasse moléculaire :327.19Gusacitinib
CAS :<p>Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM).</p>Formule :C24H28N8O2Degré de pureté :98.06% - 99.94%Couleur et forme :SolidMasse moléculaire :460.53(E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide
CAS :Formule :C17H14N2O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :294.3047Ilginatinib
CAS :<p>Ilginatinib (NS-018) is a highly active and orally bioavailable inhibitor of JAK2.</p>Formule :C21H20FN7Degré de pureté :98.4% - 99.01%Couleur et forme :SolidMasse moléculaire :389.43WHI-P154
CAS :Formule :C16H14BrN3O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :376.2047JAK2 Inhibitor V
CAS :<p>JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.</p>Formule :C23H24N2ODegré de pureté :98.36% - 99.15%Couleur et forme :SolidMasse moléculaire :344.45Golidocitinib
CAS :<p>Golidocitinib (AZD4205) is a selective JAK1 inhibitor (IC50: 73 nM) and weakly inhibits JAK2/JAK3 (IC50: >14.7, >30 μM).</p>Formule :C25H31N9O2Degré de pureté :98.87% - 99.88%Couleur et forme :SolidMasse moléculaire :489.57Ilginatinib maleate
CAS :<p>Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable inhibitor of JAK2.</p>Formule :C25H24FN7O4Degré de pureté :99.74% - 99.82%Couleur et forme :SolidMasse moléculaire :505.5Delgocitinib
CAS :<p>Delgocitinib is a potent JAK inhibitor (IC50: 2.8-58 nM), treats inflammatory diseases, and is the first topical drug for atopic dermatitis.</p>Formule :C16H18N6ODegré de pureté :99.95%Couleur et forme :SolidMasse moléculaire :310.35Nimucitinib
CAS :<p>Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.</p>Formule :C25H26F2N6O2Degré de pureté :98.71%Couleur et forme :SoildMasse moléculaire :480.51HAT-SIL-TG-1&AT
<p>HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.</p>Formule :C60H69N17O11SCouleur et forme :SolidMasse moléculaire :1236.36JAK2-IN-10
CAS :<p>JAK2-IN-10 (compound 5) is a potent inhibitor of JAK2v617f, with an IC50 value of ≤10 nM.</p>Formule :C33H33D3FN9O2Couleur et forme :SolidMasse moléculaire :612.71DBL-6-13
<p>DBL-6-13 is an inhibitor of WDR5, displaying moderate binding affinity with dissociation constants (Kd) of 6.8 μM and 9.1 μM as determined by microscale thermophoresis analysis and fluorescence polarization analysis, respectively.</p>Formule :C25H38N4O3Couleur et forme :SolidMasse moléculaire :442.59Deuruxolitinib
CAS :<p>Deuruxolitinib functions as an inhibitor of JAK1/2.</p>Formule :C17H18N6Couleur et forme :SolidMasse moléculaire :314.41MR44397
<p>MR44397 is a ligand for WD40 repeat (WDR) 5 and is applicable in cancer research.</p>Formule :C23H26N4O2SCouleur et forme :SolidMasse moléculaire :422.54FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Couleur et forme :LiquidKinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Couleur et forme :Odour SolidTyrosine Kinase Inhibitor Library
<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>Couleur et forme :Odour SolidJAK-STAT Compound Library
<p>A unique collection of 252 JAK/STAT signaling targeted compounds for high throughput and high content screening;</p>Couleur et forme :Odour SolidTyk2-IN-22
CAS :<p>Tyk2-IN-22 (Compound A8) is a selective inhibitor of tyrosine kinase 2 (Tyk2), effectively inhibiting Tyk2, JAK1, and JAK3 with IC50 values of 9.7 nM, 148.6 nM, and 883.3 nM, respectively. Additionally, Tyk2-IN-22 suppresses downstream STAT5 phosphorylation.</p>Formule :C16H16ClN5O2Couleur et forme :SolidMasse moléculaire :345.78JAK3-IN-15
<p>JAK3-IN-15 (compound 22) is a JAK3 inhibitor that reduces the secretion of p-JAK3 induced by LPS. It is utilized in research for rheumatoid arthritis.</p>Couleur et forme :Odour SolidJAK1/TYK2-IN-1
CAS :<p>JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).</p>Formule :C18H20F3N7OCouleur et forme :SolidMasse moléculaire :407.401JAK-IN-15
CAS :<p>JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).</p>Formule :C22H23FN4O3SCouleur et forme :SolidMasse moléculaire :442.51S-Ruxolitinib
CAS :<p>S-Ruxolitinib can be used in related research in the field of life sciences. Its product number is T3066 and CAS number is 1160597-27-2.</p>Formule :C17H18N6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :306.37TYK2 activator-1
<p>TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.</p>Formule :C23H21FN4O2Couleur et forme :SolidMasse moléculaire :404.16485JAK1/STAT3-IN-1
<p>JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).</p>Formule :C30H33FN4O3SCouleur et forme :SolidMasse moléculaire :548.67Axltide
CAS :<p>Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.</p>Formule :C63H107N19O20S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1514.77SJ1008030 formic
<p>SJ1008030 (compound 8) formic is a selective JAK2 degrader within the PROTAC class, demonstrating efficacy in inhibiting MHH-CALL-4 leukemia cell growth with an</p>Formule :C43H45N13O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :919.96JAK2-IN-6
CAS :<p>JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.</p>Formule :C14H10ClN3OS2Degré de pureté :99.64%Couleur et forme :SolidMasse moléculaire :335.83SJ988497
CAS :<p>SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.</p>Formule :C36H36N10O5Couleur et forme :SolidMasse moléculaire :688.74WDR5 ligand 2
CAS :<p>WDR5ligand 2 is a ligand for WDR5 and can be utilized in the synthesis of PROTAC WDR5degrader 1.</p>Formule :C29H31F3N4O4Couleur et forme :SolidMasse moléculaire :556.576SJ10542
CAS :<p>SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL - 24 nM; CRBN recruiter.</p>Formule :C41H46N12O5SCouleur et forme :SolidMasse moléculaire :818.95Pumecitinib
CAS :<p>Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.</p>Formule :C17H20N8O2SDegré de pureté :99.94%Couleur et forme :SoildMasse moléculaire :400.46SJ1008030
CAS :<p>SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.</p>Formule :C42H43N13O7SCouleur et forme :SolidMasse moléculaire :873.94TYD-68
<p>TYD-68 is a potent and selective CRBN-recruiting TYK2 PROTAC degrader, with a DC50 value of 0.42 nM. This compound effectively inhibits IL-12 and IFN-α-induced phosphorylation of STAT4 and STAT1, thereby blocking TYK2-dependent signaling pathways. TYD-68 is applicable in psoriasis research.</p>Couleur et forme :Odour SolidPROTAC TYK2 degradation agent1
CAS :<p>PROTAC TYK2 Agent1 selectively degrades TYK2, with a 14 nM DC50, for autoimmune research.</p>Formule :C55H69N13O7SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1056.28AS2553627
CAS :<p>AS2553627 is a JAK inhibitor. AS2553627 prevents chronic rejection in rat cardiac allografts.</p>Formule :C18H19N5OCouleur et forme :SolidMasse moléculaire :321.38JAK-IN-29
<p>JAK-IN-29 (Compound 3) is a potent inhibitor of Janus kinases (JAK) [1].</p>Formule :C17H14ClN5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :355.78JAK-IN-33
<p>JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1].</p>Degré de pureté :98%Couleur et forme :Odour SolidLH168
<p>LH168 is a potent and selective probe for WDR5, with a SPR Kd value of 13 nM.</p>Formule :C29H31F3N6O2SCouleur et forme :SolidMasse moléculaire :584.66JAK/HDAC-IN-4
<p>JAK/HDAC-IN-4 (compound 11 i) is a dual inhibitor targeting both JAK2 and HDAC6, with IC50 values of 0.49 nM and 12 nM respectively. It inhibits cell proliferation and the production of nitric oxide. In a mouse model induced by Imiquimod, JAK/HDAC-IN-4 ameliorates psoriasiform skin lesions with low toxicity.</p>Formule :C30H32N8O5SCouleur et forme :SolidMasse moléculaire :616.69JI069
CAS :<p>JI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.</p>Formule :C15H12Cl2N2O4SDegré de pureté :98.01%Couleur et forme :SolidMasse moléculaire :387.24Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)
CAS :<p>Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide derived from mouse JAK2, specifically composed of amino acids 475 to 491.</p>Formule :C88H138N20O34P2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :2082.1Povorcitinib phosphate
CAS :<p>Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.</p>Formule :C23H25F5N7O5PDegré de pureté :99.57%Couleur et forme :SolidMasse moléculaire :605.45JAK-2/3-IN-1
CAS :<p>JAK-2/3-IN-1 inhibits JAK-2/3 isoforms with sub-250 nM Ki; from US patent US8163732B2.</p>Formule :C20H12ClN3OCouleur et forme :SolidMasse moléculaire :345.79WHI-P180 Hydrochloride
CAS :Formule :C16H15N3O3·HClDegré de pureté :>97.0%(T)(HPLC)Couleur et forme :White to Light gray to Light yellow powder to crystalMasse moléculaire :333.77DTP3
CAS :<p>DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.</p>Formule :C26H35N7O5Couleur et forme :SolidMasse moléculaire :525.6Atinvicitinib
CAS :<p>Atinvicitinib, a selective JAK1 inhibitor, blocks cytokine signaling, modulating itch, allergy, and inflammatory responses, immune and therapeutic studies.</p>Formule :C16H17FN6O3Degré de pureté :99.36%Couleur et forme :SolidMasse moléculaire :360.35Itacitinib adipate
CAS :<p>Itacitinib adipate: oral JAK1 inhibitor, tested in phase II myelofibrosis trial.</p>Formule :C32H33F4N9O5Couleur et forme :SolidMasse moléculaire :699.66Ifidancitinib
CAS :<p>Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.</p>Formule :C20H18FN5O3Degré de pureté :98.05%Couleur et forme :SolidMasse moléculaire :395.39WHI-P154
CAS :Formule :C16H14BrN3O3Degré de pureté :>98.0%(HPLC)Couleur et forme :White to Yellow to Orange powder to crystalMasse moléculaire :376.21CHZ868
CAS :<p>CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.</p>Formule :C22H19F2N5O2Degré de pureté :99.38%Couleur et forme :SolidMasse moléculaire :423.42Ilunocitinib
CAS :<p>Ilunocitinib is a non-selective and orally active Janus kinase (JAK) inhibitor for pruritus and atopic dermatitis caused by atopic dermatitis in dogs.</p>Formule :C17H17N7O2SDegré de pureté :99.88%Couleur et forme :SolidMasse moléculaire :383.43PF-06651600 malonate
CAS :<p>PF-06651600 is a potent and selective JAK3 inhibitor.</p>Formule :C18H23N5O5Couleur et forme :SolidMasse moléculaire :389.41Pacritinib
CAS :<p>Pacritinib (SB1518) (SB1518) is an effective and specific inhibitor of JAK2 and FLT3 (IC50: 23/22 nM, in cell-free assays).</p>Formule :C28H32N4O3Degré de pureté :99.25% - 99.49%Couleur et forme :SolidMasse moléculaire :472.58Filgotinib
CAS :<p>Filgotinib (GLPG0634) is a selective JAK1 inhibitor. The IC50 values against JAK1, JAK2, JAK3, and TYK2 are 10 nM, 28 nM, 810 nM, and 116 nM, respectively.</p>Formule :C21H23N5O3SDegré de pureté :98.03% - ≥95%Couleur et forme :SolidMasse moléculaire :425.5Baricitinib phosphate
CAS :<p>Baricitinib phosphate (INCB028050) is a selective orally bioavailable JAK1/JAK2 inhibitor.</p>Formule :C16H20N7O6PSDegré de pureté :99.4% - 99.82%Couleur et forme :SolidMasse moléculaire :469.41WDR5-0103 hydrochloride[890190-22-4(free base)]
<p>WDR5-0103 hydrochloride[890190-22-4(free base)] (WD-Repeat Protein 5-0103) is an effective and specific WD repeat-containing protein 5 (WDR5) antagonist (Kd:</p>Formule :C21H26ClN3O4Degré de pureté :99.66%Couleur et forme :SolidMasse moléculaire :419.9Solcitinib
CAS :<p>Solcitinib (GLPG-0778), a JAK1 inhibitor, may treat psoriasis, ulcerative colitis, and lupus.</p>Formule :C22H23N5O2Degré de pureté :99.61% - 99.82%Couleur et forme :SolidMasse moléculaire :389.45Fosifidancitinib
CAS :<p>Fosifidancitinib is a potent inhibitor of JAK 1 and JAK 3.</p>Formule :C21H21FN5O7PDegré de pureté :99.54%Couleur et forme :SolidMasse moléculaire :505.39JAK3-IN-6
CAS :<p>JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM</p>Formule :C19H18N4O3Degré de pureté :99.94% - 99.94%Couleur et forme :SolidMasse moléculaire :350.37WHI-P97 HCl
<p>WHI-P97 HCl is a potent and selective JAK-3 inhibitor.</p>Formule :C16H14Br2ClN3O3Degré de pureté :99.49%Couleur et forme :SolidMasse moléculaire :491.56SHR0302
CAS :<p>SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3,</p>Formule :C18H22N8O2SDegré de pureté :99.11%Couleur et forme :SolidMasse moléculaire :414.48Gusacitinib HCl
CAS :<p>Gusacitinib (ASN-002/EN-3351), a potent SYK/JAK inhibitor, has strong antitumor activity in various cancers.</p>Formule :C24H29ClN8O2Couleur et forme :SolidMasse moléculaire :497Ritlecitinib
CAS :<p>Ritlecitinib (PF-06651600) is an orally available, selective JAK3 inhibitor and does not affect the activity of JAK1/2.Cost-effective and quality-assured.</p>Formule :C15H19N5ODegré de pureté :98.82% - 99.92%Couleur et forme :SolidMasse moléculaire :285.34GLPG0634 analog
CAS :<p>GLPG0634 analog (GLPG0634 analogue) is a specific JAK1 inhibitor with IC50 of 10/28/810/116 nM for JAK1/2/3 and TYK2, respectively.</p>Formule :C23H18N6O2Degré de pureté :99.52% - >99.99%Couleur et forme :SolidMasse moléculaire :410.43Ruxolitinib
CAS :<p>Ruxolitinib (INCB018424) is a JAK1/2 inhibitor (IC50=3.3/2.8 nM) that is potent and selective.</p>Formule :C17H18N6Degré de pureté :99.4% - >99.99%Couleur et forme :SolidMasse moléculaire :306.36Tofacitinib
CAS :<p>Tofacitinib (Tasocitinib) is an orally Janus kinase inhibitor. Tofacitinib is used for the treatment of rheumatoid arthritis. Cost effective and quality assured.</p>Formule :C16H20N6ODegré de pureté :99% - >99.99%Couleur et forme :SolidMasse moléculaire :312.37Itacitinib
CAS :<p>Itacitinib (INCB039110) is an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic activity.</p>Formule :C26H23F4N9ODegré de pureté :96.4% - 99.5%Couleur et forme :SolidMasse moléculaire :553.51(Z)-LFM-A13
CAS :<p>(Z)-LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.</p>Formule :C11H8Br2N2O2Degré de pureté :99.88%Couleur et forme :SolidMasse moléculaire :360Fedratinib
CAS :<p>Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.</p>Formule :C27H36N6O3SDegré de pureté :97.31% - 99.96%Couleur et forme :SolidMasse moléculaire :524.68Ritlecitinib tosylate
CAS :<p>Ritlecitinib (PF-06651600) is a potent, selective JAK3 inhibitor with proven in vivo efficacy, low clearance, and has undergone clinical trials.</p>Formule :C22H27N5O4SCouleur et forme :SolidMasse moléculaire :457.549Ruxolitinib (S enantiomer)
CAS :<p>Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.</p>Formule :C17H18N6Degré de pureté :99.37% - 99.79%Couleur et forme :SolidMasse moléculaire :306.36WHI-P154
CAS :<p>WHI-P154 (Jak3 inhibitor ii) is a potent JAK3 inhibitor.</p>Formule :C16H14BrN3O3Degré de pureté :98% - 99.67%Couleur et forme :SolidMasse moléculaire :376.2Momelotinib
CAS :<p>Momelotinib (LM-1149), an oral JAK1/2 inhibitor with IC50s 11/18 nM, blocks ATP binding, disrupting JAK-STAT pathway and reducing tumor growth.</p>Formule :C23H22N6O2Degré de pureté :97.47% - 99.56%Couleur et forme :SolidMasse moléculaire :414.46Ruxolitinib phosphate
CAS :<p>Ruxolitinib phosphate (INCB18424 phosphate) is a JAK1/2 inhibitor with IC50 of 3.3 nM/2.8 nM. Cost-effective and quality-assured.</p>Formule :C17H21N6O4PDegré de pureté :98% - >99.99%Couleur et forme :SolidMasse moléculaire :404.36BD750
CAS :<p>BD750 is an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation(IC50 of 1.5 μM and 1.1 μM in</p>Formule :C14H13N3OSDegré de pureté :99.02%Couleur et forme :SolidMasse moléculaire :271.34Abrocitinib
CAS :<p>Abrocitinib (PF-04965842) (PF-04965842) is a potent, specific and orally-active JAK1 inhibitor (IC50s: 29/803 nM for JAK1/2).</p>Formule :C14H21N5O2SDegré de pureté :99.09% - 99.91%Couleur et forme :SolidMasse moléculaire :323.41Atractylenolide I
CAS :<p>Atractylenolide-I reduces inflammation, improves sepsis, liver, and kidney function, and enhances EOC cell sensitivity to paclitaxel.</p>Formule :C15H18O2Degré de pureté :97.55% - 99.92%Couleur et forme :SolidMasse moléculaire :230.3NVP-BSK805 trihydrochloride
CAS :<p>NVP-BSK805 trihydrochloride inhibits JAK2 (0.48 nM IC50); also affects JAK1, JAK3, TYK2.</p>Formule :C27H31Cl3F2N6OCouleur et forme :SolidMasse moléculaire :599.93Upadacitinib
CAS :<p>Upadacitinib (ABT-494), a selective JAK1 inhibitor, is researched for autoimmune diseases; IC50: 43 nM.</p>Formule :C17H19F3N6ODegré de pureté :98.96% - 99.94%Couleur et forme :SolidMasse moléculaire :380.37AT9283
CAS :<p>AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).</p>Formule :C19H23N7O2Degré de pureté :99.83% - 99.98%Couleur et forme :SolidMasse moléculaire :381.43Pacritinib hydrochloride
CAS :<p>Pacritinib HCl: strong JAK2/Wild-type & JAK2V617F inhibitor (IC50: 23/19 nM), used in AML & MF research.</p>Formule :C28H32N4O3·xClHCouleur et forme :SolidRGB-286638 free base
CAS :<p>RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.</p>Formule :C29H35N7O4Degré de pureté :98% - 99.91%Couleur et forme :SolidMasse moléculaire :545.63Gandotinib
CAS :<p>LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).</p>Formule :C23H25ClFN7ODegré de pureté :99.33% - 99.86%Couleur et forme :SolidMasse moléculaire :469.94Oclacitinib
CAS :<p>Oclacitinib (PF-03394197)(PF03394197) is a potent and selective JAKs inhibitor with IC50 of 10-99 nM; not inhibit a panel of 38 non-JAK kinases (IC50 's > 1000</p>Formule :C15H23N5O2SDegré de pureté :98% - 98.45%Couleur et forme :White To Off-White SolidMasse moléculaire :337.44Cucurbitacin I
CAS :<p>Cucurbitacin I (JSI-124), a natural compound, is a selective inhibitor of JAK2/STAT3 with anti-cancer activity.</p>Formule :C30H42O7Degré de pureté :96.69% - 99.8%Couleur et forme :SolidMasse moléculaire :514.65Oclacitinib maleate
CAS :<p>Oclacitinib maleate is a selective JAK inhibitor (IC50: 10-99 nM; JAK1 cytokines: 36-249 nM), with no effect on 38 non-JAK kinases.</p>Formule :C15H23N5O2S·C4H4O4Degré de pureté :99.17%Couleur et forme :SolidMasse moléculaire :453.51CEP-33779
CAS :<p>CEP-33779 is a novel and selective inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.</p>Formule :C24H26N6O2SDegré de pureté :98.24% - ≥95%Couleur et forme :SolidMasse moléculaire :462.57Momelotinib HCl
CAS :<p>Momelotinib HCl is a JAK1/2 inhibitor, reducing anemia in myelofibrosis (MF) patients.</p>Formule :C23H24Cl2N6O2Couleur et forme :SolidMasse moléculaire :487.38Tofacitinib Citrate
CAS :<p>Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).</p>Formule :C22H28N6O8Degré de pureté :99.19% - 99.75%Couleur et forme :SolidMasse moléculaire :504.49JAK-IN-5 hydrochloride
CAS :<p>JAK-IN-5 hydrochloride is a JAK inhibitor [1].</p>Formule :C27H32ClFN6OCouleur et forme :SolidMasse moléculaire :511.03AZD-1480
CAS :<p>AZD1480: JAK2 inhibitor, IC50 0.26 nM; selective vs Tyk2, JAK3; less on JAK1. Used in solid tumors, PPV, PMF, ET trials.</p>Formule :C14H14ClFN8Degré de pureté :98.25% - 99.47%Couleur et forme :SolidMasse moléculaire :348.77RO8191
CAS :<p>RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.</p>Formule :C14H5F6N5ODegré de pureté :98% - 98.85%Couleur et forme :SolidMasse moléculaire :373.21Curculigoside
CAS :<p>1.</p>Formule :C22H26O11Degré de pureté :99.85%Couleur et forme :SolidMasse moléculaire :466.44XL019
CAS :<p>XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.</p>Formule :C25H28N6O2Degré de pureté :99.19%Couleur et forme :SolidMasse moléculaire :444.532,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS :<p>2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.</p>Formule :C16H13Cl2N3O2Degré de pureté :98.77%Couleur et forme :SolidMasse moléculaire :350.2Cerdulatinib
CAS :<p>Cerdulatinib (PRT2070) is an novel oral dual Syk/JAK inhibitor.</p>Formule :C20H27N7O3SDegré de pureté :98.74% - 99.49%Couleur et forme :SolidMasse moléculaire :445.54Protosappanin A
CAS :<p>Protosappanin A combats brain inflammation, suppresses rat heart transplant rejection, fights MRSA, and inhibits HIV with a 12.6 uM IC50.</p>Formule :C15H12O5Degré de pureté :99.42% - 99.82%Couleur et forme :SolidMasse moléculaire :272.25AMG-47a
CAS :<p>AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.</p>Formule :C29H28F3N5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :535.56Decernotinib
CAS :<p>Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.</p>Formule :C18H19F3N6ODegré de pureté :99.28% - >99.99%Couleur et forme :SolidMasse moléculaire :392.38G5-7
CAS :<p>G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.</p>Formule :C22H19F2NO3Degré de pureté :97.3%Couleur et forme :SolidMasse moléculaire :383.39(E/Z)-Zotiraciclib
CAS :<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.</p>Formule :C23H24N4ODegré de pureté :97.75% - 99.92%Couleur et forme :SolidMasse moléculaire :372.46FLLL32
CAS :<p>FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).</p>Formule :C28H32O6Degré de pureté :97% - 97.90%Couleur et forme :SolidMasse moléculaire :464.55AG490
CAS :<p>AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.</p>Formule :C17H14N2O3Degré de pureté :98.6% - 99.39%Couleur et forme :Yellow SolidMasse moléculaire :294.3GDC-0214
CAS :<p>GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).</p>Formule :C28H28ClF2N9O3Degré de pureté :99.75%Couleur et forme :SolidMasse moléculaire :612.03Baricitinib
CAS :<p>Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.</p>Formule :C16H17N7O2SDegré de pureté :99% - >99.99%Couleur et forme :SolidMasse moléculaire :371.42Peficitinib
CAS :<p>Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.</p>Formule :C18H22N4O2Degré de pureté :98.67% - 99.4%Couleur et forme :SolidMasse moléculaire :326.39Pyridone 6
CAS :<p>Pyridone 6, a selective JAK1/2/3 and Tyk2 inhibitor with IC50s: JAK1=15 nM, JAK2=1 nM, JAK3 (Ki=5 nM), Tyk2=1 nM; weakly binds other kinases (130 nM-10 μM).</p>Formule :C18H16FN3ODegré de pureté :97.1% - 98.74%Couleur et forme :SolidMasse moléculaire :309.34WHI-P97
CAS :<p>WHI-P97 is a rationally designed potent inhibitor of JAK-3.</p>Formule :C16H13Br2N3O3Degré de pureté :99.93%Couleur et forme :SolidMasse moléculaire :455.1JANEX-1
CAS :<p>JANEX-1: cell-permeable, reversible Jak3 inhibitor (IC50: 78 μM), ATP-competitive, selective; weak on JAK1/2, Zap/Syk, SRC.</p>Formule :C16H15N3O3Degré de pureté :98% - 99.81%Couleur et forme :SolidMasse moléculaire :297.31WP1066
CAS :<p>WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.</p>Formule :C17H14BrN3ODegré de pureté :98.92% - 99.73%Couleur et forme :SolidMasse moléculaire :356.22Fedratinib hydrochloride hydrate
CAS :<p>Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.</p>Formule :C27H40Cl2N6O4SDegré de pureté :98.96% - 99.87%Couleur et forme :SolidMasse moléculaire :615.61AZ960
CAS :<p>AZ960 is an effective ATP competitive JAK2 inhibitor (IC50/Ki: <3 nM and0.45 nM).</p>Formule :C18H16F2N6Degré de pureté :96.02% - 98.51%Couleur et forme :SolidMasse moléculaire :354.36ZM39923 hydrochloride
CAS :<p>ZM39923 hydrochloride (JAK3 Inhibitor IV) is an JAK1/3 inhibitor, almost no activity to JAK2 and modestly potent to EGFR; also is sensitive to transglutaminase.</p>Formule :C23H25NO·HClDegré de pureté :98.05%Couleur et forme :SolidMasse moléculaire :367.91BMS-911543
CAS :<p>BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.</p>Formule :C23H28N8ODegré de pureté :97.69% - 99.98%Couleur et forme :SolidMasse moléculaire :432.52SAR-20347
CAS :<p>SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).</p>Formule :C21H18ClFN4O4Degré de pureté :98.99% - 99.77%Couleur et forme :SolidMasse moléculaire :444.84FM-381
CAS :<p>FM381, a JAK3 inhibitor with 127 pM IC50, is 410-3600x more selective over JAK1/2/TYK2.</p>Formule :C24H24N6O2Degré de pureté :98.44%Couleur et forme :SolidMasse moléculaire :428.49TG101209
CAS :<p>TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.</p>Formule :C26H35N7O2SDegré de pureté :99% - >99.99%Couleur et forme :SolidMasse moléculaire :509.67Deucravacitinib
CAS :<p>Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor.Cost-effective and quality-assured.</p>Formule :C20H19D3N8O3Degré de pureté :98.52% - >99.99%Couleur et forme :SolidMasse moléculaire :425.46RO495
CAS :<p>RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assays</p>Formule :C17H14Cl2N6ODegré de pureté :97.94%Couleur et forme :SolidMasse moléculaire :389.24SC99
CAS :<p>SC99 inhibits JAK2-STAT3, reducing STAT3 genes, platelet activity, and has anti-myeloma, anti-thrombotic effects.</p>Formule :C15H8Cl2FN3ODegré de pureté :99.56%Couleur et forme :SolidMasse moléculaire :336.15Brevilin A
CAS :<p>Brevilin A, a sesquiterpene from Centipeda minima, hinders JAK and blocks STAT3 (IC50=10.6μM), inducing apoptosis and autophagy in cancer cells.</p>Formule :C20H26O5Degré de pureté :99.97% - >99.99%Couleur et forme :SolidMasse moléculaire :346.42Cerdulatinib hydrochloride
CAS :<p>Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 < 200 nM.</p>Formule :C20H28ClN7O3SDegré de pureté :99.85%Couleur et forme :SolidMasse moléculaire :482GS-829845
CAS :<p>GS-829845 is a JAK1 inhibitor, the main component of the active metabolite of Filgotinib, which is approximately 10-fold less potent and has a longer half-life</p>Formule :C17H19N5O2SDegré de pureté :99.93%Couleur et forme :SolidMasse moléculaire :357.43NVP-BSK805
CAS :<p>NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.</p>Formule :C27H28F2N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :490.55Solrikitug
CAS :<p>Solrikitug,Anti-CRLF2 humanized IgG1κ monoclonal antibody.</p>Degré de pureté :95%Couleur et forme :LiquidZM39923
CAS :<p>ZM39923 is a JAK3 inhibitor (pIC50: 7.1). ZM39923 also effectively inhibits tissue transglutaminase (IC50: 10 nM).</p>Formule :C23H25NODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :331.45(3S,4S)-Tofacitinib
CAS :<p>(3S,4S)-Tofacitinib, a less active enantiomer of tofacitinib, is a Janus kinases inhibitor.</p>Formule :C16H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :312.37SD-1029
CAS :<p>SD-1029 is a JAK2 inhibitor and a novel Stat3 activation inhibitor that inhibits Stat3 phosphorylation and JAK-STAT signaling.</p>Formule :C25H32Br2Cl2N2O3Couleur et forme :SolidMasse moléculaire :639.25JAK-IN-11
CAS :<p>JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.</p>Formule :C23H22FN5O4SDegré de pureté :99.75%Couleur et forme :SolidMasse moléculaire :483.52JAK-IN-20
CAS :<p>JAK-IN-20: potent oral JAK1,2,3 inhibitor with IC50s 7, 5, 14 nM respectively, good pharmacokinetics, anti-inflammatory in vivo.</p>Formule :C28H30FN7O2Couleur et forme :SolidMasse moléculaire :515.58JAK-2/3-IN-2
CAS :<p>JAK-2/3-IN-2 (Compound 3h) is a potent JAK2 & JAK3 inhibitor with IC50s of 23.85 nM (JAK2) & 18.9 nM (JAK3).</p>Formule :C19H19ClN2OSCouleur et forme :SolidMasse moléculaire :358.89Peficitinib hydrochloride
CAS :<p>Peficitinib HCl (ASP015K) is an oral JAK inhibitor with IC50s: JAK1 (3.9 nM), JAK2 (5.0 nM), JAK3 (0.7 nM), Tyk2 (4.8 nM).</p>Formule :C18H23ClN4O2Couleur et forme :SolidMasse moléculaire :362.86TK4b
CAS :<p>TK4b, a JAK inhibitor, targets leukemia/lymphoid diseases, with IC50s: 18.42 nM (JAK3) & 19.40 nM (JAK2).</p>Formule :C21H22N2O2Couleur et forme :SolidMasse moléculaire :334.41TK4g
CAS :<p>TK4g, a potent JAK inhibitor, has IC50s of 12.61 nM (JAK2) & 15.80 nM (JAK3); promising for lymphoid diseases & leukemia research.</p>Formule :C19H19N3O4SCouleur et forme :SolidMasse moléculaire :385.44JAK-IN-14
CAS :<p>JAK-IN-14 (compound 16) is a specific JAK1 inhibitor. It prevents JAK1 phosphorylation by binding to the active site of JAK in immune, inflammation and cancer.</p>Formule :C19H15FN4ODegré de pureté :98.27%Couleur et forme :SolidMasse moléculaire :334.35TyK2-IN-2
CAS :<p>TyK2-IN-2 is a selective inhibitor of TYK2 (IC50s: 7 nM, 0.1 μM, and 0.05 μM for TYK2 JH2, IL-23, and IFNα).</p>Formule :C16H18N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :310.35JAK-IN-18
CAS :<p>"JAK-IN-18: potent JAK inhibitor for eye, skin, respiratory disease research (WO2018204238A1, comp 1)."</p>Formule :C27H28F2N6O3Couleur et forme :SolidMasse moléculaire :522.55JAK3-IN-12
CAS :<p>JAK3-IN-12 (compound 15k) is a potent inhibitor of JAK3 (IC50: 9.5 nM) and can be used in the study of rheumatoid arthritis.</p>Formule :C19H19N5O4SCouleur et forme :SolidMasse moléculaire :413.45Tyk2-IN-5
CAS :<p>Tyk2-IN-5 is a selective and orally active inhibitor of Tyk2 JH2 (Ki: 0.086 nM for Tyk2 JH2; IC50: 25 nM for IFNα).</p>Formule :C21H19FN8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :434.43EP009
CAS :<p>EP009, a novel, selective, and orally active inhibitor of JAK3, induces therapeutic response in T-cell malignancies.</p>Formule :C14H24O2Couleur et forme :SolidMasse moléculaire :224.34Tyk2-IN-7
CAS :<p>Tyk2-IN-7 is an inhibitor of TYK2 JH2, binds to the TYK2 JH2 domain (IC50: 0.00053 μM; Ki.app: 0.00007 μM).</p>Formule :C18H15D3N6O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :401.46MS-1020
CAS :<p>MS-1020 inhibits JAK3/STAT3, blocks active JAK3, suppresses JAK3/STAT5 signaling, and targets STAT3 in certain cells.</p>Formule :C21H18N2O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :346.381,2,3,4,5,6-Hexabromocyclohexane
CAS :<p>Inhibits JAK2 autophosphorylation; non-cytotoxic at 100μM; 1μM reduces activity by 50%, 50μM nearly abolishes it.</p>Formule :C6H6Br6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :557.54OICR-0547
CAS :<p>OICR-0547 is an inactive derivative of OICR-9429 and is commonly used as a negative control for OICR-9429.</p>Formule :C28H29F3N4O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :542.55INCB16562
CAS :<p>INCB16562: oral JAK1/2 inhibitor, halts IL-6/STAT3 in myeloma cells, boosts drug efficacy, stunts myeloma in mice.</p>Formule :C19H11Cl2N5Couleur et forme :SolidMasse moléculaire :380.23JAK3-IN-9
CAS :<p>JAK3-IN-9, potent JAK3 inhibitor, IC50 of 1.7 nM, highly selective, low toxicity, orally bioavailable, shows anti-arthritis activity.</p>Formule :C17H23N5O4SCouleur et forme :SolidMasse moléculaire :393.46TUL01101
CAS :<p>TUL01101, a selective oral JAK1 inhibitor (IC50: 3 nM), also targets JAK2, JAK3, TYK2; for rheumatoid arthritis research.</p>Formule :C22H25F2N5O2Couleur et forme :SolidMasse moléculaire :429.46CP-690550A
CAS :<p>Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.</p>Formule :C15H21N5O2Couleur et forme :SolidMasse moléculaire :303.36GDC-4379
CAS :<p>GDC-4379 is a JAK1 inhibitor that can be used to study asthma.</p>Formule :C21H18ClF2N7O3Couleur et forme :SolidMasse moléculaire :489.86Peficitinib hydrobromide
CAS :<p>Peficitinib hydrobromide is used in the treatment of Psoriasis and Rheumatoid Arthritis.</p>Formule :C18H23BrN4O2Couleur et forme :SolidMasse moléculaire :407.312Povorcitinib
CAS :<p>Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneous lupus erythematosus (CLE) and Lichen planus (LP).</p>Formule :C23H22F5N7OCouleur et forme :SolidMasse moléculaire :507.469(2R,5S)-Ritlecitinib
CAS :<p>(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective inhibitor of JAK3 with IC 50 of 144.8 nM[1].</p>Formule :C15H19N5OCouleur et forme :SolidMasse moléculaire :285.34TYK2-IN-11
CAS :<p>TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.</p>Formule :C18H17N5O3SCouleur et forme :SolidMasse moléculaire :383.42Thi-DPPY
CAS :<p>Thi-DPPY: Potent JAK3/BTK inhibitor (IC50: 1.38/62.4 nM), anti-proliferative, anti-inflammatory, potential in IPF research.</p>Formule :C28H28ClN5O4SCouleur et forme :SolidMasse moléculaire :566.07PF-00956980
CAS :<p>PF-00956980: reversible JAK inhibitor, IC50: JAK1 (2.2μM), JAK2 (23.1μM), JAK3 (59.9μM), for lung/skin inflammation research.</p>Formule :C18H26N6OCouleur et forme :SolidMasse moléculaire :342.44SYK/JAK-IN-1
CAS :<p>SYK/JAK-IN-1 is a dual SYK/JAK inhibitor with IC50 values of less than 5 nM for both SYK and JAK2.</p>Formule :C24H26N8O3Couleur et forme :SolidMasse moléculaire :474.52JAK3-IN-1
CAS :<p>JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.</p>Formule :C26H30ClN7O2Couleur et forme :SolidMasse moléculaire :508.02JAK-IN-10
CAS :<p>JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.</p>Formule :C20H18FN5O3SDegré de pureté :99.53%Couleur et forme :SolidMasse moléculaire :427.45JAK-IN-28
CAS :<p>JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].</p>Formule :C20H18ClN7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :407.86JAK-IN-30
CAS :<p>JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50</p>Formule :C19H26N8SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :398.53JAK1-IN-4
CAS :<p>JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).</p>Formule :C26H32FN9O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :521.59JAK3/BTK-IN-2
CAS :<p>JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.</p>Formule :C25H32N8O2Degré de pureté :99.64% - 99.87%Couleur et forme :SolidMasse moléculaire :476.57Lorpucitinib
CAS :<p>Lorpucitinib (JNJ-64251330) is a JAK kinase inhibitor used in the study of inflammatory and gastrointestinal diseases.</p>Formule :C22H28N6O2Degré de pureté :99.72%Couleur et forme :SolidMasse moléculaire :408.5JAK3i
CAS :<p>JAK3i selectively inhibits JAK3 kinase, targeting the second, vital wave of STAT5 phosphorylation for T cell growth.</p>Formule :C18H15FN4O3Degré de pureté :98.61% - 99.81%Couleur et forme :SolidMasse moléculaire :354.34Jaspamycin
CAS :<p>Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.</p>Formule :C12H12N4O5Couleur et forme :SolidMasse moléculaire :292.25JAK3/BTK-IN-1
CAS :<p>JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important</p>Formule :C25H28N8ODegré de pureté :97.89%Couleur et forme :SolidMasse moléculaire :456.54Izencitinib
CAS :<p>Izencitinib (JNJ-8398) is a JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.</p>Formule :C22H26N8Degré de pureté :99.82%Couleur et forme :SolidMasse moléculaire :402.50STS-E412
CAS :<p>STS-E412 is a tissue-protective and selective EPOR/CD131 receptor activator for the study of neurological disorders.</p>Formule :C15H15ClN4O2Degré de pureté :99.01%Couleur et forme :SolidMasse moléculaire :318.76JAK1-IN-8
CAS :<p>JAK1-IN-8, a specific inhibitor of Janus kinase 1 (JAK1, IC50<500 nM).</p>Formule :C22H23FN4O3SDegré de pureté :98.4%Couleur et forme :SolidMasse moléculaire :442.51JAK-STAT-IN-1
CAS :<p>JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.</p>Formule :C21H21N5O2Degré de pureté :99.59%Couleur et forme :SolidMasse moléculaire :375.42Butyzamide
CAS :<p>Butyzamide: oral Mpl activator, non-peptide, antagonizes TPO receptors, boosts hMpl, Ba/F3 cells, and enhances platelets in mice.</p>Formule :C29H32Cl2N2O5SDegré de pureté :99.51% - 99.83%Couleur et forme :SoildMasse moléculaire :591.55JAK-IN-25
CAS :<p>JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.</p>Formule :C19H17N5O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :379.37Nezulcitinib
CAS :<p>Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.</p>Formule :C30H37N7O2Couleur et forme :SolidMasse moléculaire :527.66Upadacitinib tartrate
CAS :<p>Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.</p>Formule :C21H33F3N6O11Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :602.521JAK-IN-17
<p>"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."</p>Formule :C33H38F2N6O8Couleur et forme :SolidMasse moléculaire :684.69TCS 21311
CAS :<p>TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.</p>Formule :C27H25F3N4O4Degré de pureté :99.39% - ≥98%Couleur et forme :SolidMasse moléculaire :526.51Lepzacitinib
CAS :<p>Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.</p>Formule :C18H21N5O3Degré de pureté :99.85%Couleur et forme :SolidMasse moléculaire :355.39JAK kinase-IN-1
CAS :<p>JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32</p>Formule :C17H19F2N7OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :407.44JAK-IN-5
CAS :<p>JAK-IN-5 is a JAK inhibitor.</p>Formule :C27H31FN6ODegré de pureté :98.1% - 99.37%Couleur et forme :SolidMasse moléculaire :474.57JAK-IN-1
CAS :<p>JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.</p>Formule :C20H24N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :380.44Tubulin/JAK2-IN-1
CAS :<p>Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significant</p>Formule :C22H20N6O3Couleur et forme :SolidMasse moléculaire :416.43FM-479
CAS :<p>FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.</p>Formule :C25H26N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :442.523JAK2-IN-4
CAS :<p>JAK2-IN-4 is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.</p>Formule :C23H27N5O4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :469.56TCJL37
CAS :<p>TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.</p>Formule :C17H11ClF2N4O2Couleur et forme :SolidMasse moléculaire :376.74Brepocitinib
CAS :<p>Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).</p>Formule :C18H21F2N7ODegré de pureté :99.82%Couleur et forme :SolidMasse moléculaire :389.4ABBV-712
CAS :<p>ABBV-712 is a selective Tyrosine Kinase 2 (TYK2) inhibitor, demonstrating an IC50 value of 0.195 μM, and is implicated in the regulation of autoimmune diseases</p>Formule :C24H28N4O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :452.5Tyk2-IN-9
CAS :<p>Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.</p>Formule :C20H17N9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :383.41JAK-IN-24
CAS :<p>JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.</p>Formule :C20H25N5O2Couleur et forme :SolidMasse moléculaire :367.44JAK-IN-4
CAS :<p>JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.</p>Formule :C18H21N4Na2O6PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :466.341Itacnosertib (hydrocholide)
CAS :<p>Itacnosertib hydrochloride acts as an inhibitor targeting JAK2, ACVR1 (ALK2), and ALK5 [1].</p>Formule :C26H29ClN8OCouleur et forme :SolidMasse moléculaire :505.01Ginsenoside Rk1
CAS :<p>Ginsenoside Rk1 is a component created by processing the ginseng plant at high temperatures.</p>Formule :C42H70O12Degré de pureté :98.46% - 99.13%Couleur et forme :SolidMasse moléculaire :767JAK-IN-26
CAS :<p>JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency in</p>Formule :C22H24N6O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :420.46QL-1200186
CAS :<p>QL-1200186 is an orally active, selective TYK2 inhibitor that, upon dose-dependent oral administration, suppresses interferon-γ (IFNγ) production following</p>Formule :C26H27N7O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :485.54
![WDR5-0103 hydrochloride[890190-22-4(free base)]](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FT5140.webp&w=3840&q=75)
